Wu Chaorui, Zhang Xiaojie, Wang Tongbo, Zhou Hong, Guo Chunguang, Chen Yingtai, Zhao Dongbing
Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Transl Cancer Res. 2020 May;9(5):3312-3323. doi: 10.21037/tcr.2020.04.02.
Primary tumor resection (PTR) and lymph node dissection (LND) may be performed occasionally in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the role of PTR and LND in such cases remains unclear. Thus, we aimed to test the effect of PTR and LND on overall survival (OS) and cancer-specific survival (CSS) in mPDAC patients.
Patients with mPDAC were identified from the Surveillance Epidemiology and End Results (SEER) database (2010-2015). The inverse probability of treatment weighting (IPTW) method was used to minimize the selection bias. IPTW-adjusted Kaplan-Meier curves and Cox proportional hazards models were used to compare OS and CSS in different treatment groups.
A total of 10,036 patients met the inclusion criteria. Of these patients, 275 (2.7%) underwent PTR, while 217 (2.2%) also underwent LND with a median of 16 nodes removed. In the IPTW-adjusted Kaplan-Meier analysis, the median OS was 13 versus 6 months (P<0.001) for the PTR and non-PTR groups, respectively, and 15 versus 5 months (P=0.007) for the LND and non-LND groups, respectively. In the IPTW-adjusted Cox regression analysis, PTR was independently associated with better OS [hazard ratio (HR) 0.483, 95% confidence interval (CI): 0.468-0.498, P<0.001], as was LND (HR 0.286, 95% CI: 0.228-0.358, P<0.001). Similar results were observed in the analysis of CSS. In the LND group, the extent of LND was not associated with either OS or CSS.
PTR and LND were independent prognostic factors that prolonged OS and CSS in de novo mPDAC patients. These findings must be validated in prospective randomized studies.
对于转移性胰腺导管腺癌(mPDAC)患者,偶尔可能会进行原发肿瘤切除(PTR)和淋巴结清扫(LND)。然而,PTR和LND在这类病例中的作用仍不明确。因此,我们旨在测试PTR和LND对mPDAC患者总生存期(OS)和癌症特异性生存期(CSS)的影响。
从监测、流行病学和最终结果(SEER)数据库(2010 - 2015年)中识别出mPDAC患者。采用治疗权重逆概率(IPTW)方法以尽量减少选择偏倚。使用IPTW调整后的Kaplan - Meier曲线和Cox比例风险模型比较不同治疗组的OS和CSS。
共有10,036例患者符合纳入标准。在这些患者中,275例(2.7%)接受了PTR,而217例(2.2%)同时接受了LND,中位清扫淋巴结数为16个。在IPTW调整后的Kaplan - Meier分析中,PTR组和非PTR组的中位OS分别为13个月和6个月(P < 0.001),LND组和非LND组分别为15个月和5个月(P = 0.007)。在IPTW调整后的Cox回归分析中,PTR与更好的OS独立相关[风险比(HR)0.483,95%置信区间(CI):0.468 - 0.498,P < 0.001],LND也是如此(HR 0.286,95% CI:0.228 - 0.358,P < 0.001)。在CSS分析中观察到类似结果。在LND组中,LND的范围与OS或CSS均无关。
PTR和LND是可延长初治mPDAC患者OS和CSS的独立预后因素。这些发现必须在前瞻性随机研究中得到验证。